Results 31 to 40 of about 9,399,438 (251)

Features of multiple sclerosis in childhood in the Republic of Tatarstan

open access: yesНеврология, нейропсихиатрия, психосоматика, 2023
Multiple sclerosis (MS) in children and adolescents is a genuine concern of pediatric neurology that specialists in all countries are dealing with. To date, neither the causes of onset nor the individual components of the pathogenesis of the disease have
A. R. Khaibullina   +2 more
doaj   +1 more source

Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature

open access: yesFrontiers in Neurology, 2020
Atypical forms of demyelinating diseases with tumor-like lesions and aggressive course represent a diagnostic and therapeutic challenge for neurologists.
Aigli G. Vakrakou   +14 more
doaj   +1 more source

Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis

open access: yesFrontiers in Immunology, 2023
Current understanding of Multiple Sclerosis (MS) pathophysiology implicates perturbations in adaptive cellular immune responses, predominantly T cells, in Relapsing-Remitting forms (RRMS).
Aigli G. Vakrakou   +13 more
doaj   +1 more source

Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases

open access: yesNeurology: Neuroimmunology & Neuroinflammation, 2021
Objective To analyze serum immunoglobulin G (IgG) antibodies to major isoforms of myelin oligodendrocyte glycoprotein (MOG-alpha 1-3 and beta 1-3) in patients with inflammatory demyelinating diseases.
Kathrin Schanda   +28 more
semanticscholar   +1 more source

Heterogeneity of Baló’s concentric sclerosis: a study of eight cases with different therapeutic concepts

open access: yesBMC Neurology, 2020
Background Baló’s Concentric Sclerosis (BCS) is a rare heterogeneous demyelinating disease with a variety of phenotypes on Magnetic Resonance Imaging (MRI).
D. Tzanetakos   +11 more
doaj   +1 more source

Atypical demyelinating disease [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 1974
A 17 year old girl died after an illness characterized by progressive mental deterioration and severe myoclonic jerks. Extensive pathological, virological, and immunological studies failed to support the diagnosis of subacute sclerosing panencephalitis but were compatible with disseminated demyelinating disease.
J M, Adams   +5 more
openaire   +2 more sources

Electroneurophysiological criteria of efficiency of pathogenetic therapy in diabetic polyneuropathy. [PDF]

open access: yesĶazaķstannyṇ Klinikalyķ Medicinasy, 2016
Purpose: to estimate efficiency of pathogenetic therapy of diabetic polyneuropathy with including of benfotiaminby means of an electroneuromyography.
Lubov Kuzina, Gulnaz Kaishibayeva
doaj   +1 more source

The role of glial cells in neurodegenerative diseases. Part 2. Glial cells pathophysiology in neurodegeneration [PDF]

open access: yesFarmacja Polska, 2022
The proper operation of the nervous system is strongly dependent on the interactions between neurons and glial cells. Thus, the disturbance of their relationship leads to various neurological complications.
Mateusz Maszczyk   +2 more
doaj   +1 more source

Fulminant Demyelinating Diseases [PDF]

open access: yesThe Neurohospitalist, 2013
Fulminant demyelinating disease is a heading that covers acute disseminated encephalomyelitis and its variant acute hemorrhagic leukoencephalitis (Hurst disease), severe relapses of multiple sclerosis (MS), variants of MS (tumefactive MS, Marburg variant, Balo concentric sclerosis, myelinoclastic diffuse sclerosis), and neuromyelitis optica-spectrum ...
Megan R, Rahmlow, Orhun, Kantarci
openaire   +2 more sources

RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

open access: yesНервно-мышечные болезни, 2017
Objective. Comparison of Axoglatiran® FS (F-Sintez,  Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Ltd.,  Israel) efficiency and safety in patients with relapsing-remitting multiple sclerosis. Materials and methods. In the study 150 patients
F. A. Khabirov   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy